Kofepriz approves six clinical trials, including the evaluation of twice-yearly subcutaneous lenacapavir as pre-exposure prophylaxis (PrEP) for HIV.

He Lenacapavir is being administered prescribed along with other drugs treat human immunodeficiency virus type 1 (HIV-1) in adults and is part of a class of drugs called capsid inhibitors (the protective outer protein shell of the virus that protects the nucleic acid of the virus) HIV. Lenacapavir reduces the amount of HIV in the blood, and although it does not cure HIV, it does reduce the chance of developing acquired immunodeficiency syndrome (AIDS). and other HIV-related illnesses such as serious infections or cancer. Clinical study approved coffeeprise evaluate its efficacy and safety for PrEP when administered subcutaneously two long-acting injections per year.

On the other side, mexican regulator report documents the authorization of 24 new medicines, including a new molecule for the treatment of chronic myeloid leukemia and an innovative biotechnological agent against anemia; 121 medical devices, of which 32 are intended for health care, How thrombectomy catheters (type of surgery done to remove a blood clot from an artery or vein) and for coronary angioplasty (a procedure that improves blood flow in narrowed or blocked coronary arteries) and digital hearing aids with bone surface vibration

Among the inputs coffeeprise also authorized 59 new devices for diagnostics of toxoplasmosis, carbapenemase and measurement of sensitivity of slowly growing non-tuberculous mycobacteria, as well as 30 new medical devices such as intravascular ultrasound and spectroscopy, And mobile visualization robot Loop-X, to purchase intraoperative images This allows surgeons to obtain a large real-time field of view of the patient during surgery.

Source link

Leave a Comment